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Inotropes may be an appropriate treatment for patients with advanced heart failure
(AdHF) who remain highly symptomatic despite optimized standard therapies.
Objectives for inotrope use in these situations include relief of symptoms and im-
provement of quality of life, and reduction in unplanned hospitalizations and the
costs associated with such episodes. All of these goals must be attained without
compromising survival. Encouraging ﬁndings with intermittent cycles of intravenous
levosimendan have emerged from a range of exploratory studies and from three
larger controlled trials (LevoRep, LION-HEART, and LAICA) which offered some evi-
dence of clinical advantage. In these settings, however, obtaining statistically robust
data may prove elusive due to the difﬁculties of endpoint assessment in a complex
medical condition with varying presentation and trajectory. Adoption of a composite
clinical endpoint evaluated in a hierarchical manner may offer a workable solution
to this problem. Such an instrument can explore the proposition that repetitive ad-
ministration of levosimendan early in the period after discharge from an acute epi-
sode of worsening heart failure may be associated with greater subsequent clinical
stability vis-a`-vis standard therapy. The use of this methodology to develop a ‘stabil-
ity score’ for each patient means that all participants in such a trial contribute to
the overall outcome analysis through one or more of the hierarchical endpoints; this
has helpful practical implications for the number of patients needed and the length
of follow-up required to generate endpoint data. The LeoDOR study (NCT03437226),
outlined in this review, has been designed to explore this new approach to outcome
assessment in AdHF.
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Introduction
Patients with advanced heart failure (AdHF) are a rela-
tively small but important contingent of the wider heart
failure (HF) population, who face substantial morbidity
through continued deterioration of symptoms, frequent
hospitalization, and eventual highmortality.
AdHF presents a major challenge to patients, physicians,
and healthcare systems. Patients experience a progressive
deterioration in their quality of life (QoL), with worsening
clinical status that requires frequent and sometimes pro-
longed hospitalizations. Progression of HF leads to prolon-
gation of hospital stays,1 with consequences for the cost of
care,2 while hospitalizations for worsening HF are signifi-
cant predictors of increased mortality risk per se. Each
time a patient is hospitalized for acute decompensated HF
(ADHF) there is a risk of further worsening of myocardial
function, leading to further episodes of hospitalization.
The growing complexities of casemanagement as this cycle
repeats itself add further to the cost of care.
Present standard-of-care medical interventions relevant
to AdHF include the full repertoire of established therapies
(diuretics, angiotensin-converting enzyme inhibitors,
angiotensin-receptor blockers, angiotensin-receptor/
neprilysin inhibitors, mineralocorticoid receptor antago-
nists, beta-adrenergic blockers, and ivabradine).3 Use of
conventional adrenergic inotropes has been characterized
byworsemortality and no strong impact on hospitalization,
despite some favourable effects on haemodynamics and
symptomatic improvements in small clinical studies.4
The issuance in 2018 of a position paper on AdHF by the
Heart Failure Association of the European Society of
Cardiology (HFA-ESC) identifying new and revised concepts
in the management of AdHF has contextualized the use of
levosimendan in this situation.5
• Fresh criteria for a diagnosis of AdHF (Table 1) super-
sede previous European6 and US7 guidance. A diagnosis
of AdHF should not be based narrowly on left
ventricular ejection fraction (LVEF), but on the
patient’s symptoms, prognostic markers, the presence
of end-organ damage, and goals for therapy. (This ad-
vice is designed to give due emphasis to the phenome-
non of progressing HF despite preserved LVEF.)
• AdHF is considered an unstable condition where stan-
dard treatment is, by definition, insufficient, and ad-
ditional interventions must be considered.
• Use of vasopressors (specifically dopamine, noradren-
aline, and adrenaline) receives only limited recom-
mendation from the HFA-ESC, which notes that these
agents have been associated with worse outcomes in
observational studies and advises that their use should
be restricted to instances of cardiogenic shock [i.e.
low systolic blood pressure (SBP) with evidence of or-
gan hypoperfusion] and then only if the low blood
pressure is considered a reversible condition or if pro-
gression to mechanical circulatory support (MCS) or
transplant is planned. Dosage should be limited to the
lowest that delivers the desired clinical goals.
• The intermittent use of levosimendan for long-term
symptomatic improvement or palliation has gained in
popularity.5 Evidence for clinical benefit in terms of
survival and reduced hospitalizations from meta-
analysis and from the LION-HEART study is regarded as
suggestive and encouraging, and prima facie better
than experience with vasopressors and adrenergic ino-
tropes. These data—examined in fuller detail later in
this review—are in need of further corroboration. It is
also suggested by the HFA-ESC that studies should be
performed to ascertain if use of levosimendan in this
way may benefit patients for whom long-term MCS or
transplantation is contraindicated or infeasible.
As a calcium sensitizer that promotes inotropy through
non-adrenergic mechanisms, levosimendan may represent
a way to realize the potential benefits of inotropic support
in AdHF with fewer of the adverse effects imputed to con-
ventional inotropes. Use of levosimendan in this way may
Table 1 Criteria for a diagnosis of advanced heart failure as advised in the 2018 Position Paper of the Heart Failure Association of
the European Society of Cardiology
All the following must be present despite optimal guideline-directed treatment:
• Severe and persistent symptoms of heart failure [NYHA Grade III (advanced) or IV]
• Severe cardiac dysfunction (LVEF 30%), isolated RV failure (e.g. ARVC) or non-operable severe valve abnormalities or congenital
abnormalities or persistently high (or increasing) BNP or NT-proBNP values and data of severe diastolic dysfunction or LV struc-
tural dysfunction according to the ESC deﬁnition of HFpEF and HFmrEF.
• Episodes of pulmonary or systemic congestion requiring high-dose intravenous diuretics (or diuretic combinations) or episodes of
low output requiring inotropes or vasoactive drugs or malignant arrhythmias causing >1 unplanned visit or hospitalization in the
past 12months.
• Severe impairment of exercise capacity with inability to exercise or low 6MWT (<300 m) or pVO2 <12–14 mL/kg/min estimated
to be of cardiac origin.
[In addition to the above, extra-cardiac organ dysfunction due to heart failure (e.g. cardiac cachexia, kidney, or liver dysfunction)
or type 2 pulmonary hypertension may be present, but are not required.]
Reproduced with permission from Crespo-Leiro et al.5
LVEF, left ventricular ejection fraction; ARVC, arrhythmogenic right ventricular cardiomyopathy; BNP, brain natriuretic peptide; NT-proBNP, N-ter-
minal-pro-brain natriuretic peptide; LV, left ventricular; ESC, European Society of Cardiology; HFpEF, heart failure with preserved ejection fraction;
HFmrEF, heart failure with mid-range ejection fraction; 6MWT, 6-min walk test; PVO2, peak exercise oxygen consumption; RV, right ventricle/
ventricular.
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be regarded as a step towards the ‘decatecholaminization’
of patients with AdHF, in much the same way that has been
advocated for cardiogenic shock.8,9 Levosimendan exerts a
range of cardiovascular effects, including ventriculo-
arterial recoupling, decongestion, and cardiac protection
against ischaemia–reperfusion injury, as well as potentially
advantageous ancillary effects on kidney function, all of
which may be relevant in AdHF10,11; its effects are not im-
paired by beta-adrenergic blockade (which is likely to be
widely implemented in these patients)12; and its use and
effectiveness as an intermittent therapy are likely to be
enhanced by the existence of a long-acting active metabo-
lite designated OR-1896.13
Clinical studies on the intermittent use of
levosimendan in advanced heart failure
Indications of benefit from intermittent intravenous (i.v.)
levosimendan in AdHF in a series of preliminary studies
(see Poelzl et al.14 and Table 2 for a synopsis) stimulated
the development of a series of larger randomized trials:
LevoRep, LION-HEART, and LAICA. These three prospective,
randomized, double-blind, placebo-controlled, multi-
centre, parallel-group trials investigated repetitive ther-
apy (cycles every 2–4weeks) in similar patient populations
(Table 3)22–24 but slightly differing dose schedules in order
to cover a range of treatment possibilities. The protocol
for LevoRep specified four cycles of i.v. levosimendan
therapy. For LION-HEART, the protocol specified two addi-
tional cycles of levosimendan therapy in order to assess
the effect of a larger cumulative dose of levosimendan
(Figure 1). The study dose per cycle was identical in
LevoRep and LION-HEART (0.2mg/kg/min for 6 h at 2-week
intervals) while the LAICA study examined a lower dose ad-
ministered for longer (0.1mg/kg/min intravenously for 24h
at 30-day intervals for up to 12months; median treatment
duration 6months).
The LevoRep study (NCT01065194) randomized 120 out-
patients with AdHF [EF 35%, New York Heart Association
(NYHA) Class III–IV].22 The total study period comprised a
6-week treatment period and an 18-week follow-up pe-
riod. Follow-up visits were scheduled at 2 and 18weeks
after the treatment period. The primary outcome was a
combination of the proportion of patients with a20% im-
provement in the 6-min walk test and a 15% score in-
crease on the Kansas City Cardiomyopathy Questionnaire
(KCCQ)25 at the end of the 24-week study period. That
endpoint was reached in 19% of patients receiving levosi-
mendan and in 15.8% receiving placebo [odds ratio 1.25,
95% confidence interval (95% CI) 0.44–3.59, P¼ 0.810]
(Figure 2).
Secondary outcomes of LevoRep included event-free sur-
vival after 24weeks. The net gain with levosimendan on
Table 2 Summary particulars of preliminary studies of intermittent levosimendan in advanced heart failure
References No. of
patients
enrolled
Levosimendan dose Infusion
duration (h)
Infusion
frequency
Design
comparator
Endpoints
Nanas15 36 Bolus 6 lg then 0.2 lg/kg/
min
24 2 weeks Open-label
Dobutamine
Haemodynamics; 45-day
survival
Parissis16 25 Bolus 6 lg then 0.1 lg/kg/
min to max. 0.4 lg/kg/
min
24 3 weeks Randomized
(open-label)
Placebo
LVEF, LV dimensions and
volumes; levels of NT-
proBNP, troponin T, CRP,
IL-6
Mavrogeni17 50 Bolus 6 lg then 0.1 lg/kg/
min to max. 0.2 lg/kg/
min
24 30 days Randomized
(open-label)
Placebo
LVEF, LV dimensions and
volumes; symptoms and
QoL, RV systolic pres-
sure, mitral
regurgitation
Berger18 75 Bolus 12 lg if BP >95
mmHg. then 0.1 lg/kg/
min. Infusion-only if BP
<95 mmHg
24 4 weeks Randomized
(open-label)
Prostaglandin E1
LVEF, BNP, up-titration of
beta-blockers
Papadopoulou19 20 0.1 lg/kg/min (no loading
dose)
24 30 days Open-label
None speciﬁed
LVEF and QoL
Bonios20 63 0.2 lg/kg/min if given
with dobutamine; 0.3
lg/kg/min if given alone
6 Weekly Randomized
(open-label)
Dobutamine
Haemodynamics, survival/
freedom from LVAD at 3
and 6 months
Malfatto21 33 0.1 lg/kg/min with hourly
0.1 lg/kg/min incre-
ments to max. 0.4 lg/
kg/min
24 30 days Randomized
(open-label)
Furosemide
Haemodynamics, echocar-
diography, BNP
From Poelzl et al.14
LVEF, left ventricular ejection fraction; LV, left ventricular; NT-pro-BNP, pro-N-terminal brain natriuretic peptide; QoL, quality of life; RV, right
ventricular; BNP, brain natriuretic peptide.
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this endpoint was not statistically significant [hazard ratio
(HR) 0.50, 95% CI 0.24–1.05, P¼ 0.069 (log-rank test)].
The LION-HEART study (NCT01536132) was designed to
test the efficacy and safety of i.v. administration of repeti-
tive doses of levosimendan in outpatients with AdHF (LVEF
<35%).23 A total of 69 patients were randomized to either
levosimendan (n¼ 48) or placebo (n¼ 21) administered in
an ambulatory setting. Patients were followed for clinical
outcomes for 6months (1year for vital status as a safety
endpoint).
The study’s primary endpoint of change in N-terminal
pro-brain natriuretic peptide (NT-proBNP) from baseline
was significantly in favour of levosimendan when examined
as either baseline-adjusted area under the curve (inter-
group pre- vs. post-mean difference 1766pg/mL;
P< 0.001) or as percent change from baseline (P< 0.001)
(Figure 3). Among clinical outcomes specified as secondary
endpoints, there was a significant reduction in the com-
bined incidence of all-cause mortality and hospitalization
for HF in patients receiving levosimendan [81% vs. 45.8% at
100days, P¼ 0.015 (log-rank test)]. The reduction in hospi-
talizations for HF was significant (22.9% vs. 66.7%, HR 0.25,
95% CI 0.11–0.55; P¼ 0.001).23
LAICA (NCT00988806) evaluated the efficacy and safety
of long-term intermittent administration of levosimendan
to reduce the incidence of hospital admissions for
acute HF episodes.24 Randomized patients had diagnostic
criteria of AdHF together with at least one hospital admis-
sion for acute decompensation or HF worsening within
6months.
A total of 97 patients (levosimendan, n¼ 70; placebo,
n¼ 27) were randomly assigned to receive infusions once
every 30days in addition to optimal standard HF therapy.
The primary endpoint was the incidence of admission for
ADHF or HF worsening, defined as admission to the emer-
gency department or a hospital ward for>12h due towors-
ening of signs and symptoms of HF. No significant
difference was observed in the primary endpoint but the
findings of LAICA favoured levosimendan in terms of both
fewer admissions for ADHF and lower mortality rates: levo-
simendan, 6.6%; placebo, 22.2% (P¼ 0.0439 by log-rank
test).
Adverse events and safety profile
In aggregate, experience in these three larger trials of in-
termittent levosimendan therapy indicates that this ap-
proach was well tolerated, despite the parlous clinical
status of many patients and the widespread use of complex
polypharmacy.
In the LevoRep trial, levosimendan infusions were associ-
ated with a greater median reduction in SBP than with pla-
cebo, but the overall adverse event profiles of the two
interventions were otherwise similar.22 The median drop in
SBP was more pronounced in the levosimendan group than
with placebo [6.7mmHg, interquartile range (IQR)16.6
to 2.7mmHg, vs. –1.0mmHg, IQR 4.5 to þ3.5mmHg;
P¼ 0.01]. Active measures for symptomatic hypotension
(e.g. fluid administration or vasopressor application) were
reported in 9% of patients in both groups. The frequency
of side effects was comparable and low (<3%) in both
groups with respect to tachycardia, new-onset atrial fibril-
lation, and non-sustained ventricular tachycardia. Most
doses in both groups were completed without any adverse
events: levosimendan, 212 courses (91%); placebo, 201
courses (94%).
Levosimendan was regarded as well tolerated in LION-
HEART, with comparable frequencies of patients
experiencing an adverse event (levosimendan, 77.1%; pla-
cebo, 90.9%).23 A greater proportion of levosimendan-
treated patients needed dose reduction or interruption
due to significant hypotension (SBP<80mmHg; levosimen-
dan, 15%; placebo, 9%), although this difference did not
reach statistical significance.
Table 3 Summary of patient populations and study protocols in the LevoRep, LION-HEART, and LAICA studies of intermittent levo-
simendan infusion in advanced heart failure patients
LevoRep LION-HEART LAICA
(n¼ 120) (n¼ 69) (n¼ 97)
Baseline clinical
status
NYHA Class III or IV for >3
months
NYHA Class III or IV for >4
weeks
NYHA Class III or IV
Enrolment criteria LVEF <35% LVEF <35%Episode of pul-
monary or systemic con-
gestion requiring i.v.
vasoactive drugs within
previous 12 months
One of:
• LVEF <35%
• Diastolic function Grade III
• PCWP 16 mmHg and/or CVP 12 mmHg
• NT-proBNP >3000 ng/mL
• More than one HF hospitalization with 6 months
Levosimendan
schedule
0.2 lg/kg/min for 6 h every
2 weeks (total of 4
cycles)
0.2 lg/kg/min for 6 h every
2 weeks (total of 6
cycles)
0.1 lg/kg/min for 24 h every 30 days
Duration 24 weeks 52 weeks Median 24 weeks, maximum 52 weeks
Derived from references 22–24.
CVP, central venous pressure; HF, heart failure; i.v., intravenous; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natri-
uretic peptide; NYHA, New York Heart Association; PCWP, pulmonary capillary wedge pressure.
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The rate of adverse events in the LAICA study was com-
parable between the levosimendan and placebo groups.24
This included similar incidences of patients with an adverse
event leading to discontinuation: levosimendan, n¼ 22
(31.4%) vs. placebo, n¼ 9 (33.3%).
Of these studies, LION-HEART exerted a particularly
strong influence on the content of the 2018 HFA-ESC
Position Paper on AdHF,5 with the authors noting that ‘NT-
proBNP over time, the primary endpoint, was significantly
lower in the levosimendan group compared to the placebo
group. Patients randomized to levosimendan were also less
likely to be hospitalized for heart failure or experience a
decline in health-related quality of life compared to pla-
cebo. Adverse events were similar between groups’.
Figure 1 Illustration of the complementary designs of the LevoRep and LION-HEARTstudies.
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Registry experience with intravenous
levosimendan
Important additional insights into the impact of intermit-
tent levosimendan in AdHF have recently emerged from
the multicentre RELEVANT-HF registry.26 This initiative en-
rolled 185 ambulatory AdHF patients (148 men) who had
systolic dysfunction and who had experienced two or more
HF-related hospitalizations/emergency visits in the previ-
ous 6months despite optimal medical management. Most
of these patients (n¼ 124) were treated in a hospital or
outpatient setting, with specifically tailored intermittent
levosimendan therapy in the dose range 0.05–0.2lg/kg/
min (with no preliminary bolus) at 3–4-week intervals.
Clinical benefits were recorded in the 6months after
starting levosimendan therapy, with statistically significant
reductions in the number and duration of HF-related hospi-
talizations and in total days in hospital (Figure 4). Overall
event-free 1-year survival was 76%, though lower (62%) in
those (n¼ 37) who required adjustment of their levosimen-
dan schedule due to loss of effect. Six-month direct costs
were estimated to be reduced by an average of e1157 per
capita, with indications that savings of up to almost e4000
might be achievable in that time. Given the comparison
with historic data, however, these results should be inter-
preted with caution. (See Nieminen et al.27 for an addi-
tional recent favourable, but more conservative,
perspective on the impact of levosimendan on savings in
cost of care in 7 European countries.)
The impact of levosimendan on hospitalizations in
RELEVANT-HF conforms to the findings of a recent meta-
analysis by Silvetti et al.,28 which documented a risk ratio
of 0.4 (95% CI 0.27–0.59) for rehospitalization in the
3months following conclusion of treatment in patients who
received intermittent levosimendan vs. treatment with a
range of comparator interventions.
Taken overall, experience in these large trials has con-
firmed that repetitive application of levosimendan is feasi-
ble and safe even in an outpatient setting. Among the
randomized studies, however, only LION-HEART met its pri-
mary endpoint, but there were strong trends towards re-
duction in HF-related hospital re-admission and mortality
and clear evidence that repeat use of levosimendan
reduces NT-proBNP levels.
Delivering repetitive levosimendan therapy
The protocol provisions and experiences of the LevoRep,
LION-HEART, and LAICA studies and the RELEVANT-HF regis-
try have helped to frame a pragmatic schedule for the de-
livery of intermittent levosimendan therapy in AdHF. The
process starts with the identification of candidate patients
and the goals of therapy.
For this purpose, patients with AdHF may be identified
by the following criteria: (i) LVEF <35%; (ii) NYHA Class IV
or IIIb, or NYHAClass IIIa with frequent decompensation de-
spite optimal standard therapies; and (iii) mean SBP
>90mmHg, or 80–90mmHg if the patient has previously
tolerated levosimendan. Many candidate patients will con-
form to stages 4–7 of the classification of the Interagency
Registry for Mechanically Assisted Circulatory Support: fi-
nal selections should be guided by the criteria of controlled
trials such as LAICA and LION-HEART (Table 3).
The first objectives of therapy are to prevent disease
progression, reduce hospitalizations, and improve QoL.
Figure 2 Principal endpoint results from LevoRep (composite of per-
centage of patients with improvement in the 6-min walk test of 20% and
Kansas City Cardiomyopathy Questionnaire clinical summary score 15%)
at 2 and 18weeks after completion of four cycles of levosimendan treat-
ment during a 6-week interval. The percentages of patients who reached
the primary endpoint did not differ between the two groups (Fisher’s ex-
act test). From Altenberger et al.22
Figure 3 LION-HEART: comparison of mean NT-proBNP by visit (analysis
of covariance for repeated measures). NT-proBNP, N-terminal pro-brain
natriuretic peptide; SEM, standard error of the mean.
Figure 4 Changes in days in hospital (DIH) and number and duration of
hospital admissions for heart failure (HF) in the 6months after start of
levosimendan treatment compared to the preceding 6months in the
RELEVANT-HF registry. Data are mean6 standard deviation and non-para-
metric P-values are shown. From Oliva et al.26
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These aims should be clearly explained to the patient, but
discussion of improved survival may not be appropriate and
a decision on that point needs to be shaped by assessment
of the patient’s temperament, mood, and expectations.
This is an arena of HF where the adoption of a ‘Goals of
Care’ programme (see e.g. Dougherty et al.29) may be
highly advantageous to all concerned in furthering a proper
appreciation of the patient’s needs and goals. Subject to
the usual caveats about resource availability, a steadily
strengthening case can be made for such programmes be-
coming part of the standard of care in the management of
AdHF.
Blood tests should be performed before treatment is
started. Patients should not be treated if at this stage there
are signs of:
• severe hypotension [SBP <90 mmHg (<80 mmHg in re-
peat treatment if previous infusion was well toler-
ated)] or tachycardia
• severe renal or hepatic impairment
• hypokalaemia
• significant mechanical obstructions affecting ventricu-
lar filling or outflow
• a history of torsades de pointes.
A bolus dose of levosimendan should not be used. As pa-
tient characteristics and responses to treatment are vari-
able, the initial dosing schedule needs to be flexible. The
first-time infusion should be initiated at a rate of 0.1lg/
kg/min. If that dose is well tolerated during the first 1–2 h
it may be increased to 0.2lg/kg/min. If the initial dose is
not well tolerated (as evidenced by hypotension) it should
be halved to 0.05lg/kg/min and re-evaluated. If that
lower dose is also not tolerated then treatment should be
stopped.
Determination of the interval between courses of ther-
apy (2–4weeks) should thereafter be shaped by the trajec-
tory of symptoms in individual patients. Weight-specific
infusion rates for levosimendan are to be used.
Intermittent levosimendan therapy must take place in
the context of ongoing advice and support that includes
counselling on diet and exercise/rest schedules, as well as
QoL evaluation. Ideally, specialist nurses will perform these
tasks as part of a comprehensive HF management
programme.
Future developments: the LeoDOR study
Symptom relief is a major clinical target in the manage-
ment of AdHF but reliance on symptoms as an objective
endpoint in HF trials can be problematic: responses cannot
always be measured consistently and reliably and may not
always be an ideal primary indicator of the efficacy of an
intervention. A composite endpoint combining death and
rehospitalizations might be widely supported but presents
several interrelated drawbacks which may complicate both
the conduct of any study and the interpretation of its find-
ings (see e.g. Allen et al.30).
A solution to this challenge may be to use a composite
clinical endpoint evaluated in a hierarchical manner as in
the FIGHT trial.31 Those investigators proposed, as the
primary endpoint, a Global Rank Score (GRS) where each
patient is assigned a numerical value corresponding to their
stability index, which mirrors their respective clinical con-
ditions. Each patient is given a score value based on out-
come during follow-up, and then analysed in hierarchical
categories of (i) time to death; (ii) time to HF hospitaliza-
tion; and (iii) time-averaged proportional change in NT-
proBNP. In this way, deaths are the most important events,
followed by rehospitalizations and finally by NT-proBNP
elevation.
The GRS is easy to interpret: the higher the value, the
more stable a patient’s clinical condition. Such an instru-
ment may make it feasible to examine the hypothesis that,
compared with placebo, repetitive administration of levo-
simendan early in the period after discharge from an acute
episode of worsening HF may be associated with greater
clinical stability over the course of subsequent weeks. All
the individual components of the GRS could be explored as
secondary endpoints. This approach would create an op-
portunity to recruit an advanced but fairly stable HF popu-
lation that could be enrolled within a manageable span of
time and should have a low dropout rate by virtue of the
shorter treatment time per patient.
The LeoDOR study (NCT03437226) has been designed to
explore this proposition. As a multicentre, randomized,
double-blind, placebo-controlled, three-arm trial, LeoDOR
will evaluate the efficacy and safety of repetitive levosi-
mendan therapy given for 12weeks, either as a 6-h continu-
ous infusion at a rate of 0.2lg/kg/min every 2weeks (for 7
cycles) or as a 24-h continuous infusion at a rate of 0.1lg/
kg/min every 3weeks (for 5 cycles). The treatment arm
with a 24-h continuous infusion of levosimendan has been
included tomeet the infrastructural and economic require-
ments of countries and centres currently unable to support
ambulatory therapy in AdHF. After the cycles of treatment
(i.e. at Day 84), study medication will be stopped for all
patients. Follow-up visits will then be conducted 146 2
and 1806 14days after completion of treatment.
The primary efficacy assessment in LeoDOR is based on a
composite combined outcome metric in which all partici-
pants are ranked across three hierarchical groups in order
of importance. At the head of the ranking comes (i) time to
death or urgent heart transplantation or implantation of a
ventricular assist device, followed by (ii) time to non-fatal
HF hospitalization requiring i.v. vasoactive therapy, and
(iii) time-averaged proportional change in NT-proBNP.
Enrolment in the LeoDOR study commenced in March
2018 and is scheduled to continue until mid-2019, by which
time it is planned to have enrolled 264 patients at 28
centres in 9 European countries. Detailed particulars of the
rationale, design, and conduct of the LeoDOR trial, plus
regular progress reports, are available via www.leodor
trial.com.
Another noteworthy initiative in this area is research by
one of the authors (F. Fedele) into improved methods for
identifying patients most likely to derive benefit from in-
termittent levosimendan therapy. This centres on the de-
velopment and validation of a novel heart failure
classification, the HLM methodology. This is based on stag-
ing the heart (H), lung (L), and multiple other organs (M).
The purpose of this new instrument is to differentiate
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between patients with AdHF (in whom cardiac and systemic
dysfunction and symptoms are potentially reversible) and
those with end-stage HF (in whom they are not) as part of
the wider goal of introducing the right treatment to the
right patient at the right time.
In a development of this research, the HLM instrument
has been used to evaluate outcomes in 300 patients who re-
ceived intermittent levosimendan therapy. HLM criteria
allowed for differentiation between a subset of patients
with a good response to levosimendan and a groupwith lim-
ited or no response. These groups were indistinguishable
on the basis of baseline characteristics, HF risk factors, and
aetiology, but the difference in risk of death or rehospitali-
zation up to 12months after completion of levosimendan
therapy was very large and statistically robust (P 0.001).
These data are in need of corroboration but suggest
that the HLM classification might aid the identification of
AdHF patients who could benefit from intermittent
levosimendan.
Prevention of destabilization as a strategic
goal
An episode of HF-related hospitalization is recognized as
an opportunity to implement or revise guideline-directed
medical therapy recommended by the ESC and other
professional societies as well as to manage cardiac and
non-cardiac comorbidities with the aim of bringing the
now-stabilized patient onto a long-term plateau of clinical
stability. (See Cheema et al.32 for a recent commentary on
this subject.) In addition, however, it should be noted
(Figure 5) that destabilization is not invariably immediate:
it may be possible to identify intervals during which timely
recognition of (and intervention for) signs and symptoms of
decompensation may avoid unplanned/urgent hospitaliza-
tions due to haemodynamic crises. In particular, as
noted by Cheema et al.,32 ‘Haemodynamic congestion,
evidenced by elevated filling pressures and/or [natriuretic
peptide] elevation, may exist with or without overt signs
and symptoms of clinical congestion. . . subclinical haemo-
dynamic congestion may progress to clinical congestion re-
quiring hospital admission. . . intervention [at the]
subclinical stage may prevent this’.
This possibility may be more attainable for decompensa-
tion of primarily cardiac origin or for cases of non-
adherence to medications or fluid restriction than for
cases associated with external factors such as infection,
but recent and ongoing developments in the technology
and science of telemedicine and telemonitoring identify
this as an area where significant progress may be antici-
pated within a short span of years. Levosimendan may be
an appropriate intervention in this ‘acute but non-hospital-
ized’ situation, depending on the clinical circumstances of
an individual patient.33 The successful use of intermittent
cycles of oral or parenteral levosimendan, delivered in
the outpatient setting, speaks to the feasibility of this
intervention.
In this context, a full evaluation of the impact of using
levosimendan in combination with agents such as dobut-
amine may be instructive: useful insights on that matter
should be obtainable from post hoc analysis of data from
completed randomized trials supplementing the explor-
atory work of Nanas et al.,15 who observed survival
advantages from the use of levosimendan with dobut-
amine (45-day survival rate 61%, vs. 6% with dobutamine
only, P¼ 0.0002 in log-rank test) in patients with AdHF.
Reports of the successful use of levosimendan in combina-
tion with nesiritide for the relief of symptoms and reduc-
tion in 3-month rates of re-admission or death in 120
acute heart failure patients34 are a further intimation of
the utility and potential of levosimendan as an element in
such a strategy. Experiences in the ongoing Early
Management Strategies of Acute Heart Failure for
Patients with NSTEMI (EMSAHF) study (NCT03189901) may
provide insights into this premise.
Conclusions
We concur with the view of the HFA-ESC5 that AdHF
patients are inherently unstable. Their situation often
requires inotropic therapy. Our opinion is that such therapy
should not be limited to critical care treatment or the later
phases of rehospitalization. Advanced heart failure
patients decompensate well before being hospitalized and
preventing their rehospitalization could often mean saving
myocardial tissue viability and contractility reserve. As we
illustrate in Figure 5, there is often a crucial interval during
which the timely recognition of signs and symptoms of de-
compensation can avoid unplanned hospitalization due to
haemodynamic crisis which usually accompanies loss of
myocardial tissue. In this window of opportunity, levosi-
mendan can be a viable option to avoid the loss of contrac-
tile reserve, and the burden of rehospitalization.
Acknowledgements
The authors thank Hughes associates, Oxford, UK, for assis-
tance in the preparation of this article.
Figure 5 The variable course of decompensation in advanced heart fail-
ure means that it should be possible in many instances to identify inter-
vals during which the timely recognition of the signs and symptoms of
decompensation permit interventions that can avert unplanned hospital-
izations due to haemodynamic deterioration. T: Interval during which the
timely recognition of signs and symptoms of decompensation and its
timely treatment can avoid unplanned hospitalization due to haemody-
namic crisis, which usually accompanies loss of myocardial tissue. See
text for further discussion.
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